Literature DB >> 25529862

Spleen tyrosine kinase contributes to acute renal allograft rejection in the rat.

Sharmila Ramessur Chandran1, Greg H Tesch, Yingjie Han, Naomi Woodman, William R Mulley, John Kanellis, Kate Blease, Frank Y Ma, David J Nikolic-Paterson.   

Abstract

Kidney allografts induce strong T-cell and antibody responses which mediate acute rejection. Spleen tyrosine kinase (Syk) is expressed by most leucocytes, except mature T cells, and is involved in intracellular signalling following activation of the Fcγ-receptor, B-cell receptor and some integrins. A role for Syk signalling has been established in antibody-dependent native kidney disease, but little is known of Syk in acute renal allograft rejection. Sprague-Dawley rats underwent bilateral nephrectomy and received an orthotopic Wistar renal allograft. Recipient rats were treated with a Syk inhibitor (CC0482417, 30 mg/kg/bid), or vehicle, from 1 h before surgery until being killed 5 days later. Vehicle-treated recipients developed severe allograft failure with marked histologic damage in association with dense leucocyte infiltration (T cells, macrophages, neutrophils and NK cells) and deposition of IgM, IgG and C3. Immunostaining identified Syk expression by many infiltrating leucocytes. CC0482417 treatment significantly improved allograft function and reduced histologic damage, although allograft injury was still clearly evident. CC0482417 failed to prevent T-cell infiltration and activation within the allograft. However, CC0482417 significantly attenuated acute tubular necrosis, infiltration of macrophages and neutrophils and thrombosis of peritubular capillaries. In conclusion, this study identifies a role for Syk in acute renal allograft rejection. Syk inhibition may be a useful addition to T-cell-based immunotherapy in renal transplantation.
© 2014 The Authors. International Journal of Experimental Pathology © 2014 International Journal of Experimental Pathology.

Entities:  

Keywords:  Syk; T-cell activation; humoral rejection; macrophage; neutrophil

Mesh:

Substances:

Year:  2014        PMID: 25529862      PMCID: PMC4352352          DOI: 10.1111/iep.12110

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  35 in total

1.  R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Authors:  Sylvia Braselmann; Vanessa Taylor; Haoran Zhao; Su Wang; Catherine Sylvain; Muhammad Baluom; Kunbin Qu; Ellen Herlaar; Angela Lau; Chi Young; Brian R Wong; Scott Lovell; Thomas Sun; Gary Park; Ankush Argade; Stipo Jurcevic; Polly Pine; Rajinder Singh; Elliott B Grossbard; Donald G Payan; Esteban S Masuda
Journal:  J Pharmacol Exp Ther       Date:  2006-08-31       Impact factor: 4.030

2.  Syk tyrosine kinase required for mouse viability and B-cell development.

Authors:  A M Cheng; B Rowley; W Pao; A Hayday; J B Bolen; T Pawson
Journal:  Nature       Date:  1995-11-16       Impact factor: 49.962

3.  Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat.

Authors:  Frank Y Ma; Robert S Flanc; Greg H Tesch; Brydon L Bennett; Glenn C Friedman; David J Nikolic-Paterson
Journal:  Lab Invest       Date:  2009-02-02       Impact factor: 5.662

4.  Human neutrophil Fcgamma receptors initiate and play specialized nonredundant roles in antibody-mediated inflammatory diseases.

Authors:  Naotake Tsuboi; Kenichi Asano; Michael Lauterbach; Tanya N Mayadas
Journal:  Immunity       Date:  2008-06       Impact factor: 31.745

5.  TLR4 activation mediates kidney ischemia/reperfusion injury.

Authors:  Huiling Wu; Gang Chen; Kate R Wyburn; Jianlin Yin; Patrick Bertolino; Josette M Eris; Stephen I Alexander; Alexandra F Sharland; Steven J Chadban
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

6.  Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

Authors:  A L Feldman; D X Sun; M E Law; A J Novak; A D Attygalle; E C Thorland; S R Fink; J A Vrana; B L Caron; W G Morice; E D Remstein; K L Grogg; P J Kurtin; W R Macon; A Dogan
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

7.  An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

Authors:  Frances Rena Bahjat; Polly R Pine; Andrea Reitsma; Gail Cassafer; Muhammad Baluom; Sunny Grillo; Betty Chang; Fei Fei Zhao; Donald G Payan; Elliott B Grossbard; David I Daikh
Journal:  Arthritis Rheum       Date:  2008-05

8.  Mechanisms of complement activation, C4d deposition, and their contribution to the pathogenesis of antibody-mediated rejection.

Authors:  Kazunori Murata; William M Baldwin
Journal:  Transplant Rev (Orlando)       Date:  2009-04-10       Impact factor: 3.943

9.  Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling.

Authors:  Shijun Wang; Christoph Schmaderer; Eva Kiss; Claudia Schmidt; Mahnaz Bonrouhi; Stefan Porubsky; Norbert Gretz; Liliana Schaefer; Carsten J Kirschning; Zoran V Popovic; Hermann-Josef Gröne
Journal:  Dis Model Mech       Date:  2009-12-28       Impact factor: 5.758

10.  Distinct roles for Syk and ZAP-70 during early thymocyte development.

Authors:  Emil H Palacios; Arthur Weiss
Journal:  J Exp Med       Date:  2007-07-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.